GSK scores promising data on flu vaccines; Intrexon extends big lab lease; Curis gains milestones;

Conversation on Twitter :

 @FierceBiotech: Pfizer wins popularity contest in social media survey of patients. Item | Follow @FierceBiotech

 @JohnCFierce: In case you missed it Friday, my analysis on Q3 venture numbers (good) and top 10 deals of the quarter. Special Report | Follow @JohnCFierce

 @RyanMFierce: Quintiles reels in pharma business with IT game changers. More | Follow @RyanMFierce

> GlaxoSmithKline ($GSK) says it had garnered positive data from 5 late-stage studies of two quadrivalent flu vaccines. Story

> Intrexon, the synthetic biology company, has signed on to extend its big, 55,000-square-foot lease of lab space in Germantown, MD. Release

> Late last week Curis reported that it had achieved the first two development milestones under its agreement with The Leukemia & Lymphoma Society for the development of CUDC-907, an oral small molecule drug candidate inhibitor of PI3K and histone deacetylase. Release

Pharma News

@FiercePharma: Merck is a champion donor, charity pub says. Ranks 2nd for corporate giving, as % of pretax profits.--Forbes. More | Follow @FiercePharma

> Pfizer snags new ADHD drug in $680M NextWave deal. Story

> Novartis balks at Eylea-vs.-Lucentis data. Article

> Turkey eyes a $23B pharma sector by 2023, up from $5B. News

> Generic savings tell a different patent-loss tale. Report

Medical Device News

 @FierceMedDev: Israel's growing medical device industry gains a public stage this week. More | Follow @FierceMedDev

 @MarkHFierce: W.L. Gore has the final piece in place for its REDUCE Clinical study, to test a new stroke prevention device. More | Follow @MarkHFierce

 @DamianFierce: WuXi AppTec is making a splash in biologics, launching a cGMP plant in China. More | Follow @DamianFierce

> Edwards wins broader FDA approval for Sapien heart valve. More

> Wright takes down knee website after Stryker suit. Story

CRO News

> Lundbeck seeks partners on Alzheimer's drug after EMA rejection. Item

> Korean group enlists WCCT to spur drug development. More

> WuXi launches China's first GMP-friendly biologics plant. News

> Catalent looks to bridge industry, academia on drug delivery. Article

Biotech IT News

> Quintiles reels in pharma business with IT game changers. Story

> Appistry grabs distribution of MIT-Harvard genome toolkit. Report

> Big Pharma consortium to share cancer trial data. Article

Suggested Articles

Joe Jimenez has (another) new gig. The ex-Novartis boss joined the board of Century Therapeutics, a startup working on off-the-shelf cell therapies.

As Pfizer posts its full-year financials today, as usual it’s also sneaked in several dropped projects from its pipeline.

The short seller thinks Principia’s approach to the treatment of autoimmune diseases is “misguided” and likely to lead to clinical failures.